Depletion of SDE2 enhanced cellular sensitivity to DNA damage and suppressed tumor growth, suggesting that SDE2 may be a potential therapeutic target for hypoxic tumors (Luo et al., 2020). This evidence concerns the gene SDE2 and neoplasm.